Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

ACADIA Pharmaceuticals Inc

+ Add to Watchlist

ACAD:US

30.4300 USD 0.6200 2.00%

As of 20:10:00 ET on 01/30/2015.

Snapshot for ACADIA Pharmaceuticals Inc (ACAD)

Open: 30.8800 Day's Range: 30.3600 - 31.7300 Volume: 1,130,092
Previous Close: 31.0500 52wk Range: 15.6400 - 35.0100 1-Yr Rtn: +30.60%

Stock Chart for ACAD

No chart data available.
  • ACAD:US 30.4300
  • 1D
  • 1M
  • 1Y
31.0500
Interactive ACAD Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ACAD

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.7900
Est. EPS (USD) (12/2014) -0.9140
Est. PEG Ratio -
Market Cap (M USD) 3,036.01
Shares Outstanding (M) 99.77
30 Day Average Volume 1,354,866
Price/Book (mrq) 9.1801
Price/Sale (ttm) 26,165.7303
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 02/27/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ACAD

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ACAD

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

Uli HacksellPresident/CEOStephen R Davis "Steve"Exec VP/CFO/Chief Bus Ofcr
Terrence O MooreExec VP/Chief Commercial OfficerRoger M MillsExec VP:Dev/Chief Medical Ofcr
More Company Profile & Key Executives for ACAD

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil